Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics

Plain-language summary

This study aims to build and evaluate an early warning system for organ damage based on multi-omics data in cancer patients receiving immune checkpoint inhibitor therapy. Cancer patients receiving this immunotherapy may take part, with their treatment monitored and samples collected. This is a study without a clinical phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Hebei Medical University Fourth Hospital

Intervention

Immunotherapy Monitoring and Sample Collection

Start date

9/15/2025

Estimated completion

1/1/2029

Countries

China

Related genes

Locations

• Shijiazhuang, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

· Patients with cancer who are receiving immune checkpoint inhibitor treatment.

Exclusion Criteria:

* Active phase of severe autoimmune disease.
* Severe organ dysfunction.
* Presence of active infection.
* Pregnancy or lactation.
* Allergy to drug components.